Custom Antibody Market (2026 - 2033)

Custom Antibody Market Summary

The global custom antibody market size was valued at USD 190.1 million in 2025 and is projected to grow from USD 208.6 million in 2026 to USD 398.8 million in 2033, at a CAGR of 9.7% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 45.0% in 2025. The market is experiencing strong growth, driven by increasing demand for highly specific, reproducible, and scalable antibody solutions across drug discovery, diagnostics, and life sciences research.

The rising prevalence of chronic diseases such as cancer, autoimmune disorders, and infectious diseases is generating additional demand for innovative biologics that rely on customized antibodies for target identification, validation, and therapeutic development. Consequently, adoption of custom antibody technologies accelerates as pharmaceutical and biotechnology companies transition from conventional antibody approaches toward advanced engineered and recombinant antibody platforms that offer improved specificity, consistency, and research efficiency.

The key trend shaping the market is the increasing adoption of AI-driven antibody discovery and strategic pharma-biotech collaborations, which are transforming early-stage biologics development. For instance, in March 2026, Merck entered into a collaboration with Infinimmune to discover and develop multiple custom antibodies using an AI-driven human antibody discovery platform. The deal is structured at a potential value of up to USD 838 million in upfront and milestone payments, reflecting a strong commitment toward next-generation antibody discovery. This development highlights how large pharmaceutical companies are increasingly investing in external innovation platforms to accelerate antibody identification, optimization, and pipeline development.

Furthermore, another important driver is the growing adoption of outsourced antibody development models through the CRO/CDMO ecosystem. In response to the rising complexity and costs of pharmaceutical research and development, drug developers are increasingly outsourcing antibody discovery and production, creating significant opportunities for industry participants. Advances in DNA engineering technologies, phage display libraries, and recombinant antibody development platforms have enabled the large-scale generation of custom antibodies at competitive costs and improved efficiency.

Analyst Perspective

The market is witnessing robust growth, driven by rising demand for targeted therapeutics, increasing biomedical research investments, and expanding antibody applications in drug discovery, diagnostics, and translational research. Custom antibodies are increasingly used by research institutions, biotechnology companies, and pharmaceutical manufacturers due to their high specificity, accuracy, and ability to accelerate R&D. Growing chronic diseases, advances in oncology, and the adoption of precision medicine further support market expansion. Technological advancements in antibody engineering, recombinant production, high-throughput screening, and AI-assisted discovery are improving quality, scalability, and development efficiency. Increasing reliance on CRO/CDMO providers is also creating opportunities across the value chain, supporting sustained innovation and long-term market growth.

Type Insights

The monoclonal antibodies segment held the largest market share of over 50.0% in 2025. This dominant market share is attributed to high R&D investments by prominent market players. In addition, the rising risk of lifestyle-related chronic diseases is anticipated to heighten clinical urgency to incorporate these systems, thereby propelling the custom antibodies market over the forecast period. However, custom monoclonal antibodies are relatively expensive, resulting in higher production costs for end users. Thus, the high production cost is likely to hamper segment growth in the long run.

The recombinant antibodies segment is anticipated to witness the highest growth over the forecast period, owing to their greater specificity, reproducibility, and suitability for complex research studies. Recombinant antibodies exhibit consistent performance across batches and are therefore very popular in high-level biomedical research. Another reason for the increasing demand for these products is the ease of scaling up production, in addition to being animal-free. Advancements in gene engineering and protein expression techniques have significantly accelerated their development and improved their performance.

Service Insights

The antibody development segment accounts for over 54.0% in 2025, owing to its critical role in generating highly specific antibodies for a wide range of applications, including research, diagnostics, and therapeutics. The segment remains a cornerstone of the market, encompassing essential processes such as antigen design, antibody generation, screening, characterization, and optimization, which are vital for producing antibodies with high specificity and binding affinity. Growing demand from the pharmaceutical and biotechnology industries for specialized research reagents is expected to continue supporting segment growth. Furthermore, advancements in recombinant antibody technologies and high-throughput screening methods are improving the accuracy of development and accelerating adoption across academic and industrial research settings. For instance, in August 2025, GenScript Biotech expanded its antibody discovery capabilities by integrating advanced single B-cell screening technologies with its TurboCHO™ expression platform, enabling a faster transition from antibody screening to functional validation and streamlining custom antibody development workflows for research and therapeutic applications.

The antibody fragmentation & labeling segment is anticipated to witness strong growth, driven by its increasing use in advanced research, diagnostic assays, and targeted imaging applications. This growth is primarily attributed to the rising need for precise antibody modifications that enhance detection sensitivity, signal clarity, and visualization in research and clinical settings. Increasing adoption of fluorescence-based techniques, immunohistochemistry, and flow cytometry is further supporting demand for fragmented and labeled antibodies. In addition, advancements in labeling chemistries and conjugation technologies are improving efficiency, stability, and reproducibility, thereby expanding their applicability across a broad range of life science and diagnostic applications.

Source Insights

The rabbit source segment accounted for highest market share in 2025.The reason behind such widespread use of rabbits in antibody production is that rabbits can be used to create antibodies against any protein/peptide antigens that offer high affinity. The growing use of efficient antibody discovery platforms and the development of innovative antibody technologies are driving the rabbit-derived custom antibody segment.

The Mice are anticipated to witness the fastest CAGR over the forecast period. This growth trend is due to innovations by suppliers in antibody development process technologies, which in turn are helping with research and preclinical studies.

Application Insights

The infectious disease segment accounts for over 54.0% of the market in 2025, and is expected to maintain its leading position throughout the forecast period. The growth of this segment is driven by increasing demand for custom antibodies in disease detection, diagnostic development, vaccine research, and therapeutic applications. Expansion of antibody and antigen product portfolios, along with advancements in infectious disease research, is expected to support market growth.

The oncology is anticipated to witness the fastest CAGR over the forecast period. The rising incidence of cancer and innovation in personalized treatment are expected to be key growth drivers for oncology applications in the custom antibodies market.

End User Insights

The academic & research institutes segment accounts for over 27.0% in 2025. The increasing grant programs by companies and regulatory bodies to encourage research in custom antibodies are anticipated to be a significant growth factor for the market. The key sponsors for the research and development of custom antibodies include regional governments, venture capitalists, and companies.

Pharmaceutical & biotechnology companies represent the second most significant segment owing to the growing use of customized antibodies in drug discovery, therapeutic applications, biomarker development, and immunodiagnostic tests. The trend towards targeted treatments, biopharmaceuticals, and personalized medicines has fueled the demand for customized antibodies amongst industry participants. Increasing research and development activities, coupled with the development of the antibody pipeline, are likely to aid segment growth over the forecast period.

Regional Insights

North America dominated the custom antibody market, accounting for over 45.0% of the global revenue in 2025, driven by the presence of leading industry participants, substantial government funding, and robust research activities across the region. In addition, universities and research institutions in the U.S. and Canada are actively engaged in large-scale cancer and genomics research programs, accelerating innovation in the biotechnology sector and driving demand for advanced antibody development and high-throughput laboratory technologies. The region is expected to maintain its market leadership throughout the forecast period, supported by the rapid adoption of cutting-edge technologies, strong investments in research and development, a well-established life sciences ecosystem, and increasing demand for skilled scientific professionals.

Asia Pacific Custom Antibody Market Trends

The custom antibody market in the Asia Pacific is expected to experience the fastest growth over the forecast period, driven by growing interest from major global players seeking to strengthen their presence and expand revenue opportunities in emerging economies. Significant investments are being directed toward China and India due to rapid advancements in biotechnology capabilities, expanding research infrastructure, and sustained economic growth, which are encouraging international companies to increase their regional footprint. Furthermore, regional market participants are actively enhancing their position in the global market through technological innovation, expanded service offerings, and strategic business development initiatives. Collaborations between local biotechnology companies and international research institutions are further accelerating market expansion. Rising demand for advanced research tools, coupled with continuous improvements in life sciences infrastructure and research capabilities, is expected to support strong growth prospects across the region.

Key Custom Antibody Company Insights

The market is highly competitive and fragmented, with numerous global and regional players offering a broad portfolio of antibody development, production, and modification services. There has been a growing emphasis on the development of highly specific antibodies designed for research, diagnostic, and therapeutic applications. Companies are making substantial investments in advanced technologies to enhance the efficiency of antibody discovery and development, including recombinant antibody platforms, monoclonal antibody engineering, and high-throughput screening systems. Strategic collaborations with pharmaceutical companies, academic institutions, and biotechnology firms have also become increasingly common as market participants seek to expand their technological capabilities, strengthen innovation pipelines, and broaden the scope of their antibody-related offerings.

Key Custom Antibody Companies

The following key companies have been profiled for this study on the custom antibody market.

• Thermo Fisher Scientific Inc.

• Creative Diagnostics

• Abcam plc

• Bio-Rad Laboratories, Inc

• Kaneka Eurogentec S.A.

• YenZym Antibodies, LLC.

• Abmart

• Labcorp Drug Development

• LifeSpan BioSciences, Inc

• GenScript

Recent Developments

• In January 2026, Abcam joined the LIGAND-AI consortium to support AI-driven drug discovery by providing high-quality protein datasets and predictive modeling capabilities. This development reflects the growing integration of AI technologies into biologics research and next-generation therapeutic discovery workflows.

• In March 2025, AstraZeneca agreed to acquire EsoBiotec to strengthen its advanced biologics and cell therapy capabilities. The acquisition highlights the growing convergence of antibody engineering, immuno-oncology, and next-generation therapeutic platforms.

• In January 2025, Bio-Rad announced the launch of Nuvia wPrime 2A Media, a chromatography resin designed for biomolecule purification in research and biologics manufacturing. The technology supports downstream antibody purification processes, improving scalability, efficiency, and product quality in antibody development and production workflows.

Custom Antibody Market Report Scope

Global Custom Antibody Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities across each sub-segment from 2021 to 2033. For this study, Grand View Research has segmented the global custom antibody market report based on type, service, source, application, end user, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Monoclonal Antibodies

  • Polyclonal Antibodies

  • Recombinant Antibodies

  • Others

• Service Outlook (Revenue, USD Million, 2021 - 2033)

  • Antibody Development

  • Antibody Production & Purification

  • Antibody Fragmentation & Labeling

• Source Outlook (Revenue, USD Million, 2021 - 2033)

  • Mice

  • Rabbit

  • Others

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Oncology

  • Infectious Diseases

  • Neurology

  • Stem cells

  • Immunology

  • Cardiovascular Diseases

  • Others

• End-user Outlook (Revenue, USD Million, 2021 - 2033)

  • Pharmaceutical & Biotechnology Companies

  • Academic & Research Institutes

  • CRO

  • Hospitals And Clinics

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait